Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 193

1.

DNA damage accumulation during fractionated low-dose radiation compromises hippocampal neurogenesis.

Schmal Z, Isermann A, Hladik D, von Toerne C, Tapio S, Rübe CE.

Radiother Oncol. 2019 Aug;137:45-54. doi: 10.1016/j.radonc.2019.04.021. Epub 2019 May 4.

PMID:
31063923
2.

[Radiotherapy after tumour prostheses-status, indication, coordination].

Niewald M, Melchior P, Dzierma Y, Kremp S, Rübe C.

Orthopade. 2019 Jul;48(7):605-609. doi: 10.1007/s00132-019-03722-9. Review. German.

PMID:
30919000
3.

Favorable radiation field decrease in gastric marginal zone lymphoma : Experience of the German Study Group on Gastrointestinal Lymphoma (DSGL).

Reinartz G, Pyra RP, Lenz G, Liersch R, Stüben G, Micke O, Willborn K, Hess CF, Probst A, Fietkau R, Jany R, Schultze J, Rübe C, Hirt C, Fischbach W, Bentz M, Daum S, Pott C, Tiemann M, Möller P, Neubauer A, Wilhelm M, Willich N, Berdel WE, Eich HT.

Strahlenther Onkol. 2019 Jun;195(6):544-557. doi: 10.1007/s00066-019-01446-5. Epub 2019 Mar 11.

PMID:
30859254
4.

Monte-Carlo simulation of the Siemens Artiste linear accelerator flat 6 MV and flattening-filter-free 7 MV beam line.

Sadrollahi A, Nuesken F, Licht N, Rübe C, Dzierma Y.

PLoS One. 2019 Jan 8;14(1):e0210069. doi: 10.1371/journal.pone.0210069. eCollection 2019.

5.
6.

Imaging dose and secondary cancer risk in image-guided radiotherapy of pediatric patients.

Dzierma Y, Mikulla K, Richter P, Bell K, Melchior P, Nuesken F, Rübe C.

Radiat Oncol. 2018 Sep 5;13(1):168. doi: 10.1186/s13014-018-1109-8.

7.

Oncostatin M treatment increases the responsiveness toward cisplatin-based chemoradiotherapy in cervical cancer cells in a STAT3-dependent manner.

Stroeder R, Walch-Rückheim B, Fischbach J, Juhasz-Böss I, Rübe C, Solomayer EF, Smola S.

Oncol Lett. 2018 Sep;16(3):3351-3358. doi: 10.3892/ol.2018.8987. Epub 2018 Jun 18.

8.

Clustered DNA damage concentrated in particle trajectories causes persistent large-scale rearrangements in chromatin architecture.

Timm S, Lorat Y, Jakob B, Taucher-Scholz G, Rübe CE.

Radiother Oncol. 2018 Dec;129(3):600-610. doi: 10.1016/j.radonc.2018.07.003. Epub 2018 Jul 23.

PMID:
30049456
9.

Evaluation of boost irradiation in patients with intermediate-risk stage III Wilms tumour with positive lymph nodes only: Results from the SIOP-WT-2001 Registry.

Dávila Fajardo R, Oldenburger E, Rübe C, López-Yurda M, Pritchard-Jones K, Bergeron C, Graf N, van Grotel M, van Tinteren H, Saunders D, van den Heuvel-Eibrink MM, Janssens GO, Oldenburger F.

Pediatr Blood Cancer. 2018 Aug;65(8):e27085. doi: 10.1002/pbc.27085. Epub 2018 Apr 25.

PMID:
29693799
10.

Increasing genomic instability during cancer therapy in a patient with Li-Fraumeni syndrome.

Schuler N, Palm J, Schmitz S, Lorat Y, Rübe CE.

Clin Transl Radiat Oncol. 2017 Nov 2;7:71-78. doi: 10.1016/j.ctro.2017.10.004. eCollection 2017 Dec.

11.

Image guidance in clinical practice - Influence of positioning inaccuracy on the dose distribution for prostate cancer.

Bell K, Dzierma Y, Morlo M, Nüsken F, Licht N, Rübe C.

Phys Med. 2018 Feb;46:81-88. doi: 10.1016/j.ejmp.2018.01.015.

PMID:
29519414
12.

Position paper: Rationale for the treatment of children with CCSK in the UMBRELLA SIOP-RTSG 2016 protocol.

Gooskens SL, Graf N, Furtwängler R, Spreafico F, Bergeron C, Ramírez-Villar GL, Godzinski J, Rübe C, Janssens GO, Vujanic GM, Leuschner I, Coulomb-L'Hermine A, Smets AM, de Camargo B, Stoneham S, van Tinteren H, Pritchard-Jones K, van den Heuvel-Eibrink MM; International Society of Paediatric Oncology–Renal Tumour Study Group (SIOP–RTSG).

Nat Rev Urol. 2018 May;15(5):309-319. doi: 10.1038/nrurol.2018.14. Epub 2018 Feb 27. Review.

PMID:
29485128
13.

Hair Follicle Stem Cell Faith Is Dependent on Chromatin Remodeling Capacity Following Low-Dose Radiation.

Schuler N, Timm S, Rübe CE.

Stem Cells. 2018 Apr;36(4):574-588. doi: 10.1002/stem.2768. Epub 2018 Jan 12.

14.

Abdominal imaging dose in radiology and radiotherapy - Phantom point dose measurements, effective dose and secondary cancer risk.

Dzierma Y, Minko P, Ziegenhain F, Bell K, Buecker A, Rübe C, Jagoda P.

Phys Med. 2017 Nov;43:49-56. doi: 10.1016/j.ejmp.2017.10.019. Epub 2017 Oct 27.

PMID:
29195562
15.

Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol.

van den Heuvel-Eibrink MM, Hol JA, Pritchard-Jones K, van Tinteren H, Furtwängler R, Verschuur AC, Vujanic GM, Leuschner I, Brok J, Rübe C, Smets AM, Janssens GO, Godzinski J, Ramírez-Villar GL, de Camargo B, Segers H, Collini P, Gessler M, Bergeron C, Spreafico F, Graf N; International Society of Paediatric Oncology — Renal Tumour Study Group (SIOP–RTSG).

Nat Rev Urol. 2017 Dec;14(12):743-752. doi: 10.1038/nrurol.2017.163. Epub 2017 Oct 31. Review.

PMID:
29089605
16.

Optimization of rituximab for the treatment of DLBCL: increasing the dose for elderly male patients.

Pfreundschuh M, Murawski N, Zeynalova S, Ziepert M, Loeffler M, Hänel M, Dierlamm J, Keller U, Dreyling M, Truemper L, Frickhofen N, Hünerlitürkoglu AN, Schmitz N, Pöschel V, Rixecker T, Berdel C, Rübe C, Held G, Zwick C.

Br J Haematol. 2017 Nov;179(3):410-420. doi: 10.1111/bjh.14860. Epub 2017 Oct 8.

PMID:
28990173
17.

High-dose treatment for malignant rhabdoid tumor of the kidney: No evidence for improved survival-The Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH) experience.

Furtwängler R, Kager L, Melchior P, Rübe C, Ebinger M, Nourkami-Tutdibi N, Niggli F, Warmann S, Hubertus J, Amman G, Leuschner I, Vokuhl C, Graf N, Frühwald MC.

Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26746. Epub 2017 Aug 26.

PMID:
28843054
18.

Magnetic Resonance Lymphography at 9.4 T Using a Gadolinium-Based Nanoparticle in Rats: Investigations in Healthy Animals and in a Hindlimb Lymphedema Model.

Müller A, Fries P, Jelvani B, Lux F, Rübe CE, Kremp S, Giovanoli P, Buecker A, Menger MD, Laschke MW, Frueh FS.

Invest Radiol. 2017 Dec;52(12):725-733. doi: 10.1097/RLI.0000000000000398.

19.

Histone variant H2A.J accumulates in senescent cells and promotes inflammatory gene expression.

Contrepois K, Coudereau C, Benayoun BA, Schuler N, Roux PF, Bischof O, Courbeyrette R, Carvalho C, Thuret JY, Ma Z, Derbois C, Nevers MC, Volland H, Redon CE, Bonner WM, Deleuze JF, Wiel C, Bernard D, Snyder MP, Rübe CE, Olaso R, Fenaille F, Mann C.

Nat Commun. 2017 May 10;8:14995. doi: 10.1038/ncomms14995.

20.

Retrospective analysis of stereotactic ablative radiotherapy (SABR) for metastatic lung lesions (MLLs) in comparison with a contemporaneous cohort of primary lung lesions (PLLs).

Oskan F, Dzierma Y, Wagenpfeil S, Rübe C, Fleckenstein J.

J Thorac Dis. 2017 Mar;9(3):742-756. doi: 10.21037/jtd.2017.03.07.

21.

Cancer of unknown primary (CUP) of the head and neck: retrospective analysis of 81 patients.

Al Kadah B, Papaspyrou G, Linxweiler M, Schick B, Rübe C, Büchler BS, Niewald M.

Eur Arch Otorhinolaryngol. 2017 Jun;274(6):2557-2566. doi: 10.1007/s00405-017-4525-8. Epub 2017 Mar 17.

PMID:
28314959
22.

Influence of daily imaging on plan quality and normal tissue toxicity for prostate cancer radiotherapy.

Bell K, Heitfeld M, Licht N, Rübe C, Dzierma Y.

Radiat Oncol. 2017 Jan 10;12(1):7. doi: 10.1186/s13014-016-0757-9.

23.

Ultrastructural Insights into the Biological Significance of Persisting DNA Damage Foci after Low Doses of Ionizing Radiation.

Lorat Y, Schanz S, Rübe CE.

Clin Cancer Res. 2016 Nov 1;22(21):5300-5311. Epub 2016 May 19.

24.

Clustered double-strand breaks in heterochromatin perturb DNA repair after high linear energy transfer irradiation.

Lorat Y, Timm S, Jakob B, Taucher-Scholz G, Rübe CE.

Radiother Oncol. 2016 Oct;121(1):154-161. doi: 10.1016/j.radonc.2016.08.028. Epub 2016 Sep 13.

PMID:
27637859
25.

mARC Treatment of Hypopharynx Carcinoma with Flat and Flattening-Filter-Free Beam Energies - A Planning Study.

Bell K, Fleckenstein J, Nuesken F, Licht N, Rübe C, Dzierma Y.

PLoS One. 2016 Oct 14;11(10):e0164616. doi: 10.1371/journal.pone.0164616. eCollection 2016.

26.

The Impact of Diffusion-Weighted MRI on the Definition of Gross Tumor Volume in Radiotherapy of Non-Small-Cell Lung Cancer.

Fleckenstein J, Jelden M, Kremp S, Jagoda P, Stroeder J, Khreish F, Ezziddin S, Buecker A, Rübe C, Schneider GK.

PLoS One. 2016 Sep 9;11(9):e0162816. doi: 10.1371/journal.pone.0162816. eCollection 2016.

27.

Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer.

Fleckenstein J, Petroff A, Schäfers HJ, Wehler T, Schöpe J, Rübe C.

BMC Cancer. 2016 Jun 2;16:348. doi: 10.1186/s12885-016-2379-x.

28.

STAT3/IRF1 Pathway Activation Sensitizes Cervical Cancer Cells to Chemotherapeutic Drugs.

Walch-Rückheim B, Pahne-Zeppenfeld J, Fischbach J, Wickenhauser C, Horn LC, Tharun L, Büttner R, Mallmann P, Stern P, Kim YJ, Bohle RM, Rübe C, Ströder R, Juhasz-Böss I, Solomayer EF, Smola S.

Cancer Res. 2016 Jul 1;76(13):3872-83. doi: 10.1158/0008-5472.CAN-14-1306. Epub 2016 May 23.

29.

Bericht über die sofortige Bestrahlung eines schnell wachsenden Sarkoms der Kopfhaut vor dem Wundverschluss.

Müller CS, Jungmann J, Pföhler C, Mohammad F, Rübe C, Vogt T.

J Dtsch Dermatol Ges. 2016 May;14(5):539-42. doi: 10.1111/ddg.12786_g. No abstract available.

PMID:
27119489
30.

Report on immediate irradiation of a rapidly growing sarcoma of the scalp prior to wound closure.

Müller CS, Jungmann J, Pföhler C, Mohammad F, Rübe C, Vogt T.

J Dtsch Dermatol Ges. 2016 May;14(5):539-42. doi: 10.1111/ddg.12786.

PMID:
27119488
31.

mARC prostate treatment planning with Varian Eclipse for flat vs. FFF beams.

Bell K, Dzierma Y, Palm J, Nuesken F, Licht N, Rübe C.

Phys Med. 2016 Mar;32(3):474-8. doi: 10.1016/j.ejmp.2016.02.011. Epub 2016 Apr 1.

PMID:
27053450
32.

Benchmarking the mARC performance - treatment time and dosimetric linearity.

Dzierma Y, Nuesken F, Licht N, Rübe C.

Z Med Phys. 2016 Dec;26(4):339-348. doi: 10.1016/j.zemedi.2016.02.001. Epub 2016 Mar 3.

PMID:
26947444
33.

Set-up errors and planning margins in planar and CBCT image-guided radiotherapy using three different imaging systems: A clinical study for prostate and head-and-neck cancer.

Dzierma Y, Beyhs M, Palm J, Niewald M, Bell K, Nuesken F, Licht N, Rübe C.

Phys Med. 2015 Dec;31(8):1055-1059. doi: 10.1016/j.ejmp.2015.09.002. Epub 2015 Oct 23.

PMID:
26476789
34.

IMRT and 3D conformal radiotherapy with or without elective nodal irradiation in locally advanced NSCLC: A direct comparison of PET-based treatment planning.

Fleckenstein J, Kremp K, Kremp S, Palm J, Rübe C.

Strahlenther Onkol. 2016 Feb;192(2):75-82. doi: 10.1007/s00066-015-0900-9. Epub 2015 Oct 5.

PMID:
26438071
35.

VMAT to arclet plan conversion in a treatment planning system : Feasibility and dosimetric relationship between VMAT, arclet, and stationary fields.

Dzierma Y, Licht N, Norton I, Nuesken F, Rübe C, Fleckenstein J.

Strahlenther Onkol. 2015 Dec;191(12):961-9. doi: 10.1007/s00066-015-0889-0. Epub 2015 Sep 7.

PMID:
26346775
37.

Persistent DNA Damage in Spermatogonial Stem Cells After Fractionated Low-Dose Irradiation of Testicular Tissue.

Grewenig A, Schuler N, Rübe CE.

Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1123-1131. doi: 10.1016/j.ijrobp.2015.04.033. Epub 2015 Apr 25.

PMID:
26059351
38.

Development of curative therapies for Ewing sarcomas by interdisciplinary cooperative groups in Europe.

Bölling T, Braun-Munzinger G, Burdach S, Calaminus G, Craft A, Delattre O, Deley MC, Dirksen U, Dockhorn-Dworniczak B, Dunst J, Engel S, Faldum A, Fröhlich B, Gadner H, Göbel U, Gosheger G, Hardes J, Hawkins DS, Hjorth L, Hoffmann C, Kovar H, Kruseova J, Ladenstein R, Leuschner I, Lewis IJ, Oberlin O, Paulussen M, Potratz J, Ranft A, Rössig C, Rübe C, Sauer R, Schober O, Schuck A, Timmermann B, Tirode F, van den Berg H, van Valen F, Vieth V, Willich N, Winkelmann W, Whelan J, Womer RB.

Klin Padiatr. 2015 May;227(3):108-15. doi: 10.1055/s-0035-1545263. Epub 2015 May 18.

PMID:
25985445
39.

Nanoscale analysis of clustered DNA damage after high-LET irradiation by quantitative electron microscopy--the heavy burden to repair.

Lorat Y, Brunner CU, Schanz S, Jakob B, Taucher-Scholz G, Rübe CE.

DNA Repair (Amst). 2015 Apr;28:93-106. doi: 10.1016/j.dnarep.2015.01.007. Epub 2015 Jan 28.

PMID:
25659339
40.

Image quality and dose distributions of three linac-based imaging modalities.

Dzierma Y, Ames E, Nuesken F, Palm J, Licht N, Rübe C.

Strahlenther Onkol. 2015 Apr;191(4):365-74. doi: 10.1007/s00066-014-0798-7. Epub 2014 Dec 20.

PMID:
25527311
41.

Hepatotoxicity after liver irradiation in children and adolescents : results from the RiSK.

Rösler P, Christiansen H, Kortmann RD, Martini C, Matuschek C, Meyer F, Rübe C, Langer T, Koch R, Eich HT, Willich N, Steinmann D.

Strahlenther Onkol. 2015 May;191(5):413-20. doi: 10.1007/s00066-014-0796-9. Epub 2014 Dec 9.

PMID:
25487695
42.

Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial.

Wiegel T, Bartkowiak D, Bottke D, Thamm R, Hinke A, Stöckle M, Rübe C, Semjonow A, Wirth M, Störkel S, Golz R, Engenhart-Cabillic R, Hofmann R, Feldmann HJ, Kälble T, Siegmann A, Hinkelbein W, Steiner U, Miller K.

Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):288-94. doi: 10.1016/j.ijrobp.2014.09.039. Epub 2014 Nov 20.

PMID:
25445556
43.

mARC vs. IMRT radiotherapy of the prostate with flat and flattening-filter-free beam energies.

Dzierma Y, Bell K, Palm J, Nuesken F, Licht N, Rübe C.

Radiat Oncol. 2014 Nov 26;9:250. doi: 10.1186/s13014-014-0250-2.

44.

Clinical and genetic features of rhabdoid tumors of the heart registered with the European Rhabdoid Registry (EU-RHAB).

Bartelheim K, Sumerauer D, Behrends U, Kodetova D, Kucera F, Leuschner I, Neumayer P, Oyen F, Rübe C, Siebert R, Schneppenheim R, Seeringer A, Vasovcak P, Frühwald MC.

Cancer Genet. 2014 Sep;207(9):379-83. doi: 10.1016/j.cancergen.2014.04.005. Epub 2014 Apr 21.

PMID:
24972932
45.

The role of radiotherapy and intrathecal CNS prophylaxis in extralymphatic craniofacial aggressive B-cell lymphomas.

Murawski N, Held G, Ziepert M, Kempf B, Viardot A, Hänel M, Witzens-Harig M, Mahlberg R, Rübe C, Fleckenstein J, Zwick C, Glass B, Schmitz N, Zeynalova S, Pfreundschuh M.

Blood. 2014 Jul 31;124(5):720-8. doi: 10.1182/blood-2013-10-535021. Epub 2014 Jun 17.

PMID:
24939657
46.

Dental status, dental treatment procedures and radiotherapy as risk factors for infected osteoradionecrosis (IORN) in patients with oral cancer - a comparison of two 10 years' observation periods.

Niewald M, Mang K, Barbie O, Fleckenstein J, Holtmann H, Spitzer WJ, Rübe C.

Springerplus. 2014 May 23;3:263. doi: 10.1186/2193-1801-3-263. eCollection 2014.

47.

Commissioning and first clinical application of mARC treatment.

Dzierma Y, Nuesken FG, Kremp S, Palm J, Licht NP, Rübe C.

Strahlenther Onkol. 2014 Oct;190(11):1046-52. doi: 10.1007/s00066-014-0662-9. Epub 2014 Apr 29.

PMID:
24777584
48.

Acute and late side effects to salivary glands and oral mucosa after head and neck radiotherapy in children and adolescents. Results of the "Registry for the evaluation of side effects after radiotherapy in childhood and adolescence".

Bölling T, Weege J, Eich HT, Timmermann B, Meyer FM, Rübe C, Kortmann RD, Fischedick K, Rödel C, Koch R, Willich N.

Head Neck. 2015 Aug;37(8):1137-41. doi: 10.1002/hed.23715. Epub 2014 Jul 11.

PMID:
24764129
49.

Even low doses of radiation lead to DNA damage accumulation in lung tissue according to the genetically-defined DNA repair capacity.

Flockerzi E, Schanz S, Rübe CE.

Radiother Oncol. 2014 May;111(2):212-8. doi: 10.1016/j.radonc.2014.03.011. Epub 2014 Apr 17.

PMID:
24746565
50.

Comparative planning of flattening-filter-free and flat beam IMRT for hypopharynx cancer as a function of beam and segment number.

Dzierma Y, Nuesken FG, Fleckenstein J, Melchior P, Licht NP, Rübe C.

PLoS One. 2014 Apr 10;9(4):e94371. doi: 10.1371/journal.pone.0094371. eCollection 2014.

Supplemental Content

Support Center